Function of JunB in transient amplifying cell senescence and progression of human prostate cancer

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4408-4416

  Konishi, Noboru ^a,b   Shimada, Keiji ^a   Nakamura, Mitsutoshi ^a   Ishida, Eiwa ^a   Ota, Ichiro ^a   Tanaka, Nobumichi ^a   Fujimoto, Kiyohide ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR JUNB; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL CLONING; CELL EXPANSION; CELL ISOLATION; CELL POPULATION; CHORIOALLANTOIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENESCENCE; CELL AGING; CELL TRANSFORMATION; DISEASE COURSE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; ONCOGENE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION; GENES, JUN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 51649089443     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4120     Document Type: Article

References (50)

1. Berges RR, Vukanovic J, Epstein Jl, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1: 473-80.
2. Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004;91: 196-205.
3. Tang DG, Patrawala L, Calhoun T, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007;46:1-14
4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
5. + cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
6. Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol 2006;2: 723-31.
7. Bonkhoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994;24:114-8.
8. Konishi N, Nakamura M, Kishi M, et al. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol 2002;160:1207-14.
9. Konishi N, Cho M, Yamamoto K, et al. Genetic changes in prostate cancer. Pathol Int 1997;47: 735-47.
10. Mathon NF, Lloyd AC. Cell senescence and cancer. Nat Rev Cancer 2001;1:203-13.
11. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005;26:867-74.
12. Artandi SE, DePinho RA. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 2000;10:39-46.
13. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res1991;196:33-9.
14. Slagboom PE, Droog S, Boomsma Dl. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet 1994;55:876-82.
15. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest 2004;113: 160-8.
16. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-8.
17. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003;13: 1549-56.
18. Lloyd AC. Limits to lifespan. Nat Cell Biol 2002;4: E25-7.
19. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003;22:4212-22.
20. Takahashi A, Ohtani N, Yamakoshi K, et al. Mitogenic signaling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006;8:1291-7.
21. Wei W, Herbig U, Wei S, et al. Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts. EMBO Rep 2003;4: 1061-6.
22. Colombo P, Patriarca C, Alfano RM, et al. Molecular disorders in transitional vs. peripheral zone prostate adenocarcinoma. Int J Cancer 2001;94:383-9.
23. Kirschenbaum A, Liu XH, Yao S, et al. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. Carcinogenesis 2006;27:216-24.
24. Collins AT, Habib FK, Maitland NJ, et al. Identification and isolation of human prostate epithelial stem cells based on α(2)β(1)-integrin expression. J Cell Sci 2001;114:3865-72.
25. Konishi N, Nakamura M, Ishida E, et al. High expression of a new marker PCA-1 in human prostate carcinoma. Clin Cancer Res 2005;11:5090-7.
26. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
27. Epstein Jl, Allsbrook WC, Jr., Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29: 1228-42.
28. 2- terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate 2003;55:265-80.
29. 2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 2003;24:1067-75.
30. Shimada K, Matsuyoshi S, Nakamura M, et al. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 2005:206: 423-32.
31. Hood JD, Frausto R, Kiosses WB, et al. Differential av integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 2003;162: 933-43.
32. Konishi N, Tsujikawa K, Yamamoto H, et al. Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas. Br J Cancer 2003; 88:1223-8.
33. Richardson GD, Robson CN, Lang SH, et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539-45.
34. Litvinov IV, Vander Griend DJ, Xu Y, et al. Lowcalcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006;66:8598-607.
35. Bakiri L. Matsuo K, Wisniewska M, et al Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol 2002;22:4952-64
36. Passegue E. Wagner EF. Jun B suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J 2000;19:2969-79.
37. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings J Cell Sci 2004. 117;5965-73.
38. Bond J. Jones C, Haughton M, et al. Direct evidence from siRNA-directed "knock down" that p16(INK4a) is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation. Exp Cell Res 2004;292:151-6.
39. Brookes S, Rowe J, Ruas M, et al. INK4a-deficient human diploid fibroblasts are resistant to RAS- induced senescence. EMBO J 2002;21 2936-45
40. Wei W, Sedivy JM. Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. Exp Cell Res 1999;253:519-22.
41. Morris M, Hepburn P. Wynford-Thomas D Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function. Oncogene 2002;21:4277-88.
42. Maurelli R, Zambruno G. Guerra L, et al. Inactivation of p16INK4a (inhibitor of cyclin-dependent kinase 4A) immortalizes primary human keratinocytes by maintaining cells in the stem cell compartment FASEB J 2006;20:1516-8.
43. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390 400.
44. Yogev O, Anzi S, Inoue K, et al. Induction of transcriptionally active Jun proteins regulates druginduced senescence J Biol Chem 2006;281: 34475-83.
45. Konishi N, Shimada K, Ishida E, et al Molecular pathology of prostate cancer Pathol Int 2005;55: 531-9.
46. Tiniakos DG, Mitropoulos D, Kyroudi-Voulgan A. et al. Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate. Urology 2006: 67:204-8.
47. Edwards J. Krishna NS, Mukherjee R. et al. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol 2004;204:153-8.
48. Passegue E, Jochum W, Schorpp-Kistner M, et al Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking jun B expression in the myeloid lineage. Cell 2001;104:21-32
49. 2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 2006;66:10902-10
50. Zhang G, Fahmy RG, diGirolamo N, et al jun siRNA regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation J Cell Sci 2006;119:3219-26.